Subject: VPHi: register for the AVICENNA MEMBERS-ONLY Webinar "Medtronic’s Approach to In Silico Trials"

Dear VPHi members,

I wish to remind you that today at 16 CET the Avicenna Alliance will host the first webinar of its webinar series for members-only. This monthly initiative has the goal to enable both Avicenna member companies and VPHi Members to get to know each other better and share their knowledge about their main activities, expertise and interests. The series will alternate presentations by academia and industry members, starting this month with Medtronic. If you are willing to contribute to the series, please don't hesitate to get in touch with me, providing a title and a short abstract.

Webinar title "Innovation Through Computer Modeling and Simulation at Medtronic".
by Markus Reiterer and his colleagues Mark Palmer and Benyamin Grosman from Medtronic


We kindly invite you not to share this registration link with colleagues who are not VPHi members.

Webinar programme:
Part 1:
Title: Innovation Through Collaboration
Presenter: Markus Reiterer, Ph.D., Dist. Scientist, Corp. Science & Technology, Medtronic, PLC

Medtronic, a leading medical technology, company has a 70-year history of innovation. From the beginning on all innovation was founded on intense collaboration between the physician and the engineer. By disrupting ourselves we maintained leadership in several different therapy areas over decades.

Part 2:
Title: Computer Modeling as Regulatory Evidence
Presenter: Mark Palmer, M.D., Ph.D., Dist. Scientist, Corp. Science & Technology, Medtronic, PLC
A large portion of Medtronic’s research is focused on generating evidence for safety and efficacy and more recently also for the long-term effectiveness and economic viability of therapies we provide. Computer modeling and simulation has become an important factor in this process.

Part 3:
Title: Virtual Patients Derived from the CareLink Database
Presenter: Benymin Grosman, Ph.D., Dist. Scientist, Diabetes, Medtronic, PLC
The Medtronic CareLink™ database has been used to generate a total of 7485 virtual patients with known demographics for in silico trials.
Insulin action speed and meal absorption rates used in the mathematical model were validated with published literature. The virtual patients’ predictions were validated using data from the ASPIRE Clinical Trial1 and from the MiniMed™ 670G hybrid closed-loop (HCL) study2.

Garg, Brazg, Bailey et al., Reduction in duration of hypoglycemia by automatic suspension of insulin deliver: the in-clinic ASPIRE study. Diabetes Technol Ther, 2012.
Bergenstal, Garg, Weinzimer et al., Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes, JAMA, 2016.

Don't hesitate to get in touch if you have any questions.
Best regards

In silico medicine will be the future
Virtual Physiological Human Institute for Integrative Biomedical Research (VPH Institute)

Celestijnenlaan 300C, 3001, Heverlee, Belgium
You may unsubscribe or change your contact details at any time.